Skip to main content
logo
Vivozon Pharmaceutical Co., Ltd. (KOSDAQ:082800)
South Korea flag South Korea · Delayed Price · Currency is KRW
3,100.00
+150.00 (5.08%)
At close: Sep 4, 2026

Vivozon Pharmaceutical Financials Overview

Millions KRW. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
50,34459,34387,60171,31851,56457,560
Revenue Growth
-39.54%-32.26%22.83%38.31%-10.42%32.04%
Gross Profit
18,14424,18445,40731,32121,43719,639
Operating Income
-18,889-19,166-1,8004,709-9,806-19,615
Net Income
-32,826-32,424-9,982-3,357-39,906-69,457
Earnings Per Share
-621.40-654.88-209.00-70.35-917.27-2130.00
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
10,7035,1589,98817,72126,40064,055
Total Debt
33,47142,34136,50041,61560,31084,115
Net Cash (Debt)
-22,768-37,183-26,512-23,894-33,910-20,060
Net Cash Growth
------
Net Cash Per Share
-431.01-751.00-555.09-500.74-779.45-615.13

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-10,844-6,8695,7312,992-3,323-17,496
Capital Expenditures
-630.86-1,412-8,450-4,523-6,491-10,111
Free Cash Flow
-11,475-8,281-2,719-1,532-9,814-27,608
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
36.04%40.75%51.83%43.92%41.57%34.12%
Operating Margin
-37.52%-32.30%-2.05%6.60%-19.02%-34.08%
Pretax Margin
-65.04%-54.39%-12.03%-3.03%-49.15%-131.77%
Profit Margin
-65.20%-54.64%-11.39%-4.71%-77.39%-120.67%
FCF Margin
-22.79%-13.95%-3.10%-2.15%-19.03%-47.96%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
3.703.383.882.032.893.23